Prognostic significance of B7-H3 expression in patients with colorectal cancer: A meta-analysis

Fan, Huishou; Zhu, Jianhua; Yao, Xueqing

doi:10.12669/pjms.326.11511

Cited by 24 publications

(15 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B7-H3, as one of the crucial immune checkpoint proteins, plays a critical role in the occurrence and development of CRC. Clinically, the expression of B7-H3 was associated with unfavorable outcomes in CRC patients (12,26). However, there was no relationship between B7-H3 expression and OS in this study, which might be attributed to low sample size or the uncertainty of repeated experiments.…”

Section: Discussioncontrasting

confidence: 61%

Clinical and Prognostic Relevance of B7-H3 and Indicators of Glucose Metabolism in Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

Objective: This study aimed to investigate the clinical and prognostic relevance of B7-H3 expression and indicators of glucose metabolism in patients with colorectal cancer (CRC). Methods: Using immunohistochemistry, the expression of B7-H3 was detected in a total of 213 formalin-fixed paraffin-embedded CRC tissue specimens. Furthermore, levels of fasting blood glucose (FBG), lactic dehydrogenase (LDH), and fructosamine (FMN) as indicators of glucose metabolism were analyzed in CRC patients and stratified into high or low expression subgroups based on Youden Index. The relationship between B7-H3, FBG, LDH, FMN expression, and clinicopathological characteristics were also evaluated to establish their prognostic significance in patients with CRC. Results: B7-H3 was highly expressed in CRC tissue. The positive rates of B7-H3 expression was 63.8% (136/213). We found a linear correlation between B7-H3 and FBG in depth of tumor invasion (T3/4) (p = 0.037, r = 0.259), lymph node metastasis (N0) (p = 0.004, r = 0.259), and TNM stage (I/II) (p = 0.009, r = 0.242). High expression of FBG, LDH, FMN [hazard ratio (HR) = 1.916, 95% CI: 1.223-3.00, p = 0.005; HR = 1.801, 95% CI: 1.153-2.813, p = 0.010; HR = 2.154, 95% CI: 1.336-3.472, p = 0.002], respectively, was identified as a significant independent predictor of poor overall survival (OS). Although B7-H3 expression did not affect OS, CRC patients expressing both high B7-H3 and high FMN contributed to a significant decrease in OS (HR = 1.881, 95%CI: 1.059-3.339, p = 0.031). Moreover, with low expression of B7-H3, high expression of FBG, LDH and FMN were also recognized as predictors of inferior OS (HR = 3.393, 95% CI: 1.493-7.709, p = 0.004; HR = 7.107, 95% CI: 2.785-18.138, p = 0.000; HR = 2.800, 95% CI: 1.184-6.625, p = 0.019). Conclusion: B7-H3 combined with FBG, LDH, or FMN, could reflect the clinical outcomes of patients with CRC.

show abstract

Section: Discussioncontrasting

confidence: 61%

Clinical and Prognostic Relevance of B7-H3 and Indicators of Glucose Metabolism in Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…B7-H3 expression is significantly associated with poor outcome in patients with RCC (28–30), lung cancer (31), prostate cancer (32), CRC (33, 34), gallbladder cancer (35), esophageal squamous cancer (36), cervical cancer (37), osteosarcoma (OS) (38) and breast cancer (39). Thus, B7-H3 expression might be a feasible and effective means to predict the prognosis in cancer patients.…”

Section: B7-h3mentioning

confidence: 99%

New B7 Family Checkpoints in Human Cancers

Dong

2017

Molecular Cancer Therapeutics

198

201

View full text Add to dashboard Cite

T cells are the main effector cells in immune response against tumors. The activation of T cells is regulated by the innate immune system through positive and negative costimulatory molecules. Targeting immune checkpoint regulators such as programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) has achieved notable benefit in a variety of cancers, which leads to multiple clinical trials with antibodies targeting the other related B7/CD28 family members. Recently five new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7, were identified. Here we review recent understanding of new B7 family checkpoint molecules since they have come to the front of cancer research with the concept that tumor cells exploit them to escape immune surveillance. The aim of this article is to address the structure and expression of the new B7 family molecules as well as their roles in controlling and suppressing immune responses of T cells as well as NK cells. We also discuss clinical significance and contribution of these checkpoint expressions in human cancers.

show abstract

“…A study using tissue microarray analysis in CRC demonstrated that B7-H3 expression was correlated with clinical pathology and patient outcomes (23). Similarly, a meta-analysis including 1,202 total CRC cases showed that B7-H3 in CRC patients was obviously related to 24-and 72month OS (25), demonstrating that CRC patients overexpressing B7-H3 may have a poor survival rate. In addition, nuclear localization of B7-H3 (23) and aberrant expression of B7-H3 in CD133 + CRC cells (26) were found to be closely associated with tumor progression and strongly predicted poor outcomes in CRC.…”

Section: B7 Homologmentioning

confidence: 99%

Potential Therapeutic Targets of B7 Family in Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway blockade has impressively benefited cancer patients with a wide spectrum of tumors. However, its efficacy in colorectal cancer (CRC) is modest, and only a small subset of patients benefits from approved checkpoint inhibitors. Newer checkpoints that target additional immunomodulatory pathways are becoming necessary to activate durable antitumor immune responses in patients with CRC. In this review, we evaluated the mRNA expression of all 10 reported B7 family members in human CRC by retrieving and analyzing the TCGA database and reviewed the current understanding of the top three B7 family checkpoint molecules (B7-H3, VISTA, and HHLA2) with the highest mRNA expression, introducing them as putative therapeutic targets in CRC.

show abstract

Prognostic significance of B7-H3 expression in patients with colorectal cancer: A meta-analysis

Cited by 24 publications

References 39 publications

Clinical and Prognostic Relevance of B7-H3 and Indicators of Glucose Metabolism in Colorectal Cancer

Clinical and Prognostic Relevance of B7-H3 and Indicators of Glucose Metabolism in Colorectal Cancer

New B7 Family Checkpoints in Human Cancers

Potential Therapeutic Targets of B7 Family in Colorectal Cancer

Contact Info

Product

Resources

About